Travoprost + Timolol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Ocular HTN; Open-angle glaucoma Instill 1 drop into affected eye(s) once daily.
Dosage Details
Ophthalmic
Ocular hypertension, Open-angle glaucoma
Adult: Instill 1 drop in the conjunctival sac of the affected eye(s) once daily, given at the same time each day.
Contraindications
Reactive airway disease including existing or history of bronchial asthma; severe COPD; sinus bradycardia, sick sinus syndrome including sino-atrial block, 2nd- or 3rd-degree AV block (not controlled by pacemaker); overt cardiac failure, cardiogenic shock; severe allergic rhinitis, corneal dystrophies. Pregnancy.
Special Precautions
Patient w/ 1st degree heart block, severe peripheral circulatory disorders (e.g. severe forms of Raynaud's disease/syndrome), mild/moderate COPD, corneal disease, labile diabetes or those who are subject to spontaneous hypoglycaemia. Aphakic patients, pseudoaphakic patients w/ torn posterior lens capsule or anterior chamber lenses or to those at risk for cystoid macular oedema. Lactation.
Adverse Reactions
Eye pain, ocular hyperaemia, dry eye, ocular discomfort, eye pruritus.
Patient Counseling Information
May cause gradual change in eye colour. Remove contact lenses prior to application then wait for 15 min before reinsertion. This drug may cause temporary blurred vision or other visual disturbances, if affected, do not drive or operate machinery.
Drug Interactions
Potential additive effect w/ oral Ca channel blockers, β-adrenergic blockers, antiarrhythmics, digitalis glycosides, parasympathomimetics, guanethidine. May potentiate hypertensive reaction to sudden withdrawal of clonidine. May potentiate systemic β-blockade w/ CYP2D6 inhibitors (e.g. quinidine, paroxetine). Risk of mydriasis w/ epinephrine. May increase the hypoglycaemic effect of antidiabetic agents.
Action
Description: Travoprost is a prostaglandin F analogue which reduces the intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. Timolol is a non-selective adrenergic blocking agent which acts by reducing aqueous humour formation and increasing outflow facility.
Pharmacokinetics:
Absorption: Absorbed through the cornea. Timolol: Time to peak plasma concentration: Approx 0.69 hr.
Metabolism: Timolol: Extensively metabolised in the liver.
Excretion: Travoprost: Via urine (<2% as free acid). Elimination half-life: Approx 45 min. Timolol: Via urine (approx 20% as unchanged drug and the remainder as metabolites). Terminal elimination half-life: Approx 4 hr.
Chemical Structure

Chemical Structure Image
Travoprost

Source: National Center for Biotechnology Information. PubChem Database. Travoprost, CID=5282226, https://pubchem.ncbi.nlm.nih.gov/compound/Travoprost (accessed on Jan. 23, 2020)


Chemical Structure Image
Timolol

Source: National Center for Biotechnology Information. PubChem Database. Timolol, CID=33624, https://pubchem.ncbi.nlm.nih.gov/compound/Timolol (accessed on Jan. 21, 2020)

Storage
Store between 2-25°C.
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
References
Anon. Travoprost and Timolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/03/2016.

Disclaimer: This information is independently developed by MIMS based on Travoprost + Timolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in